We are analyzing https://link.springer.com/article/10.1186/s13046-019-1360-3.

Title:
Sequential combination of cisplatin with eugenol targets ovarian cancer stem cells through the Notch-Hes1 signalling pathway | Journal of Experimental & Clinical Cancer Research
Description:
Background Ovarian carcinomas are the deadliest gynecological malignancies owing to their high rate of recurrence and high resistance to platinum-based chemotherapy. Recent studies have shown platinum-dependent enrichment of ovarian tumors with side population as well as cancer stem cells, which are highly resistant to the treatment. To overcome this treatment-limiting factor, we sought to combine cisplatin with eugenol, a natural substance known to have anti-cancer effects. Methods The efficiency of combining cisplatin with eugenol was first tested in vitro on two ovarian cancer cell lines SKOV3 and OV2774 using the WST1 and the flow cytometry techniques. The effect of this combination on ovarian cancer stem cells was determined by the tumorsphere formation assay, while the implication of the Notch pathway was evaluated post-ectopic expression of the Hes1 gene. The resulting changes in the expression of several markers was assessed by immunoblotting, immunofluorescence as well as quantitative RT-PCR. Cell sorting was also used to isolate specific ovarian cancer sub-population of cells. Furthermore, tumor-bearing mouse models were utilized to prove the potential therapeutic value of the cisplatin/eugenol combination treatment in vivo. Results We have shown that adding eugenol to cisplatin-treated ovarian cancer cells synergistically inhibited their growth and survival through induction of apoptosis. Importantly, this sequential inhibition strongly reduced the proportion of side population cells and suppressed cisplatin-dependent enrichment in ovarian cancer stem cells. Additionally, while increase in the level of Hes1 promoted stemness and enhanced resistance to cisplatin, cisplatin/eugenol cotreatment inhibited the Notch-Hes1 pathway and strongly downregulated the drug resistance ABC transporter genes. These findings were confirmed in vivo by showing that cisplatin/eugenol cotherapy inhibited tumor growth in animals, reduced the proportion and self-renewal capacities of cancer stem cells and significantly improved disease-free survival of tumor-bearing animals compared with either therapy alone. Conclusions These results indicate that cisplatin/eugenol sequential combination could be of great therapeutic value for ovarian cancer patients through targeting the Notch-Hes1 pathway and the consequent elimination of the resistant cancer stem cells.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Health & Fitness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

cells, cisplatin, eugenol, cancer, combination, fig, cell, ovarian, treatment, treated, article, additional, notch, hes, resistance, skov, tumor, file, google, scholar, stem, pathway, hesgfp, figure, aldh, growth, drug, analyzed, sorted, tumors, expression, ocscs, spheres, effects, group, results, gfp, analysis, csc, shown, control, assay, reduced, proportion, bar, cotreatment, mice, survival, selfrenewal, significantly,

Topics {✒️}

potent anti-cancer molecule mir-93/pten/akt signaling pathway γ-secretase complex consisting γ-secretase complex inhibitor article google scholar abc transporters abcg1/mdr1 full size image evaluated post-ectopic expression article download pdf γ-secretase complex proteins verapamil-sensitive abc-transporters ameliorates disease-free survival ameliorated disease-free survival increases tumor-free survival semi-solid agarose medium table s4c-i-iv suppressed cisplatin-dependent enrichment notch-hes1 signalling pathway shown platinum-dependent enrichment suppressed cisplatin-related promotion cancer stem cells ultra-low attachment plates tumor-bearing mouse models tumor-free survival analysis serous ovarian cancer eugenol treatment-dependent targeting platinum-based chemotherapy platinum-based chemotherapy [5 suppress cisplatin-dependent promotion stem cell technologies full access ovarian cancer cells privacy choices/manage cookies dose dense chemotherapy ovarian cancer patients cd44+/aldh+ yellow line nf-kb signaling pathway cisplatin/eugenol-dependent targeting mir-137 mediates cisplatin/eugenol cotreatment inhibited r-statistical software r- statistical software monotherapy-treated mice regrew eugenol strongly suppressed grew small colonies cisplatin-pre-treated cells tumor-bearing animals compared acquired chemotherapy resistance oc stem cells human tumor cells

Questions {❓}

What is it, who to treat and how to measure benefit?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Sequential combination of cisplatin with eugenol targets ovarian cancer stem cells through the Notch-Hes1 signalling pathway
         description:Ovarian carcinomas are the deadliest gynecological malignancies owing to their high rate of recurrence and high resistance to platinum-based chemotherapy. Recent studies have shown platinum-dependent enrichment of ovarian tumors with side population as well as cancer stem cells, which are highly resistant to the treatment. To overcome this treatment-limiting factor, we sought to combine cisplatin with eugenol, a natural substance known to have anti-cancer effects. The efficiency of combining cisplatin with eugenol was first tested in vitro on two ovarian cancer cell lines SKOV3 and OV2774 using the WST1 and the flow cytometry techniques. The effect of this combination on ovarian cancer stem cells was determined by the tumorsphere formation assay, while the implication of the Notch pathway was evaluated post-ectopic expression of the Hes1 gene. The resulting changes in the expression of several markers was assessed by immunoblotting, immunofluorescence as well as quantitative RT-PCR. Cell sorting was also used to isolate specific ovarian cancer sub-population of cells. Furthermore, tumor-bearing mouse models were utilized to prove the potential therapeutic value of the cisplatin/eugenol combination treatment in vivo. We have shown that adding eugenol to cisplatin-treated ovarian cancer cells synergistically inhibited their growth and survival through induction of apoptosis. Importantly, this sequential inhibition strongly reduced the proportion of side population cells and suppressed cisplatin-dependent enrichment in ovarian cancer stem cells. Additionally, while increase in the level of Hes1 promoted stemness and enhanced resistance to cisplatin, cisplatin/eugenol cotreatment inhibited the Notch-Hes1 pathway and strongly downregulated the drug resistance ABC transporter genes. These findings were confirmed in vivo by showing that cisplatin/eugenol cotherapy inhibited tumor growth in animals, reduced the proportion and self-renewal capacities of cancer stem cells and significantly improved disease-free survival of tumor-bearing animals compared with either therapy alone. These results indicate that cisplatin/eugenol sequential combination could be of great therapeutic value for ovarian cancer patients through targeting the Notch-Hes1 pathway and the consequent elimination of the resistant cancer stem cells.
         datePublished:2019-08-30T00:00:00Z
         dateModified:2019-08-30T00:00:00Z
         pageStart:1
         pageEnd:14
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s13046-019-1360-3
         keywords:
            Notch
            Hes1
            Cisplatin
            Eugenol
            Ovarian cancer stem cells
            Cancer Research
            Immunology
            Apoptosis
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-019-1360-3/MediaObjects/13046_2019_1360_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-019-1360-3/MediaObjects/13046_2019_1360_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-019-1360-3/MediaObjects/13046_2019_1360_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-019-1360-3/MediaObjects/13046_2019_1360_Fig4_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-019-1360-3/MediaObjects/13046_2019_1360_Fig5_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-019-1360-3/MediaObjects/13046_2019_1360_Fig6_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-019-1360-3/MediaObjects/13046_2019_1360_Fig7_HTML.png
         isPartOf:
            name:Journal of Experimental & Clinical Cancer Research
            issn:
               1756-9966
            volumeNumber:38
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Syed S. Islam
               affiliation:
                     name:King Faisal Specialist Hospital and Research Centre
                     address:
                        name:Cancer Biology and Experimental Therapeutics, Department of Molecular Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Abdelilah Aboussekhra
               affiliation:
                     name:King Faisal Specialist Hospital and Research Centre
                     address:
                        name:Cancer Biology and Experimental Therapeutics, Department of Molecular Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Sequential combination of cisplatin with eugenol targets ovarian cancer stem cells through the Notch-Hes1 signalling pathway
      description:Ovarian carcinomas are the deadliest gynecological malignancies owing to their high rate of recurrence and high resistance to platinum-based chemotherapy. Recent studies have shown platinum-dependent enrichment of ovarian tumors with side population as well as cancer stem cells, which are highly resistant to the treatment. To overcome this treatment-limiting factor, we sought to combine cisplatin with eugenol, a natural substance known to have anti-cancer effects. The efficiency of combining cisplatin with eugenol was first tested in vitro on two ovarian cancer cell lines SKOV3 and OV2774 using the WST1 and the flow cytometry techniques. The effect of this combination on ovarian cancer stem cells was determined by the tumorsphere formation assay, while the implication of the Notch pathway was evaluated post-ectopic expression of the Hes1 gene. The resulting changes in the expression of several markers was assessed by immunoblotting, immunofluorescence as well as quantitative RT-PCR. Cell sorting was also used to isolate specific ovarian cancer sub-population of cells. Furthermore, tumor-bearing mouse models were utilized to prove the potential therapeutic value of the cisplatin/eugenol combination treatment in vivo. We have shown that adding eugenol to cisplatin-treated ovarian cancer cells synergistically inhibited their growth and survival through induction of apoptosis. Importantly, this sequential inhibition strongly reduced the proportion of side population cells and suppressed cisplatin-dependent enrichment in ovarian cancer stem cells. Additionally, while increase in the level of Hes1 promoted stemness and enhanced resistance to cisplatin, cisplatin/eugenol cotreatment inhibited the Notch-Hes1 pathway and strongly downregulated the drug resistance ABC transporter genes. These findings were confirmed in vivo by showing that cisplatin/eugenol cotherapy inhibited tumor growth in animals, reduced the proportion and self-renewal capacities of cancer stem cells and significantly improved disease-free survival of tumor-bearing animals compared with either therapy alone. These results indicate that cisplatin/eugenol sequential combination could be of great therapeutic value for ovarian cancer patients through targeting the Notch-Hes1 pathway and the consequent elimination of the resistant cancer stem cells.
      datePublished:2019-08-30T00:00:00Z
      dateModified:2019-08-30T00:00:00Z
      pageStart:1
      pageEnd:14
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s13046-019-1360-3
      keywords:
         Notch
         Hes1
         Cisplatin
         Eugenol
         Ovarian cancer stem cells
         Cancer Research
         Immunology
         Apoptosis
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-019-1360-3/MediaObjects/13046_2019_1360_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-019-1360-3/MediaObjects/13046_2019_1360_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-019-1360-3/MediaObjects/13046_2019_1360_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-019-1360-3/MediaObjects/13046_2019_1360_Fig4_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-019-1360-3/MediaObjects/13046_2019_1360_Fig5_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-019-1360-3/MediaObjects/13046_2019_1360_Fig6_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-019-1360-3/MediaObjects/13046_2019_1360_Fig7_HTML.png
      isPartOf:
         name:Journal of Experimental & Clinical Cancer Research
         issn:
            1756-9966
         volumeNumber:38
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Syed S. Islam
            affiliation:
                  name:King Faisal Specialist Hospital and Research Centre
                  address:
                     name:Cancer Biology and Experimental Therapeutics, Department of Molecular Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Abdelilah Aboussekhra
            affiliation:
                  name:King Faisal Specialist Hospital and Research Centre
                  address:
                     name:Cancer Biology and Experimental Therapeutics, Department of Molecular Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Journal of Experimental & Clinical Cancer Research
      issn:
         1756-9966
      volumeNumber:38
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:King Faisal Specialist Hospital and Research Centre
      address:
         name:Cancer Biology and Experimental Therapeutics, Department of Molecular Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
         type:PostalAddress
      name:King Faisal Specialist Hospital and Research Centre
      address:
         name:Cancer Biology and Experimental Therapeutics, Department of Molecular Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Syed S. Islam
      affiliation:
            name:King Faisal Specialist Hospital and Research Centre
            address:
               name:Cancer Biology and Experimental Therapeutics, Department of Molecular Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
               type:PostalAddress
            type:Organization
      name:Abdelilah Aboussekhra
      affiliation:
            name:King Faisal Specialist Hospital and Research Centre
            address:
               name:Cancer Biology and Experimental Therapeutics, Department of Molecular Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Cancer Biology and Experimental Therapeutics, Department of Molecular Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
      name:Cancer Biology and Experimental Therapeutics, Department of Molecular Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

External Links {🔗}(115)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.36s.

LINK . SPRINGER . COM {}